Lineage Cell Therapeutics (LCTX) Short term Debt (2014 - 2021)
Lineage Cell Therapeutics (LCTX) posted quarterly Short term Debt of $523000.0 for Q1 2021, little changed quarter-over-quarter from $523000.0 in Q4 2020.
Lineage Cell Therapeutics (LCTX) Short term Debt (2014 - 2021) Analysis & Trends
Lineage Cell Therapeutics' Short term Debt history runs 4 years deep, the most recent figure standing at $523000.0 for Q1 2021.
- In Q1 2021, Short term Debt changed N/A year-over-year to $523000.0; the TTM figure through Mar 2021 stood at $523000.0 (changed N/A YoY), while the FY2020 annual figure was $523000.0, changed N/A from the prior year.
- Short term Debt for Q1 2021 stood at $523000.0, roughly flat from $523000.0 in the prior quarter.
- The five-year high for Short term Debt was $523000.0 in Q2 2020, with the low at $523000.0 in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Lineage Cell Therapeutics | 270.61 Mn | 212.77 Mn | 1.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 523,000.00 |
| Dec 31, 2020 | 523,000.00 |
| Sep 30, 2020 | 523,000.00 |
| Jun 30, 2020 | 523,000.00 |
| Dec 31, 2015 | 26,000.00 |
| Jun 30, 2015 | 3,000.00 |
| Mar 31, 2015 | 17,307.00 |
| Dec 31, 2014 | 31,000.00 |
| Sep 30, 2014 | 44,963.00 |
| Jun 30, 2014 | 57,500.00 |